Prosecution Insights
Last updated: November 04, 2026
Application No. 18/592,177

Unbacked and Modifiable Tapes and Skin Dressings

Non-Final OA §103§DOUBLEPATENT
Filed
Feb 29, 2024
Priority
Jan 18, 2012 — provisional 61/588,121 +6 more
Examiner
MENSH, ANDREW J
Art Unit
3781
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Worldwide Innovative Healthcare Inc.
OA Round
1 (Non-Final)
64%
Grant Probability
Moderate
1-2
OA Rounds
10m
Est. Remaining
84%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allowance Rate
388 granted / 603 resolved
-5.7% vs TC avg
Strong +19% interview lift
Without
With
+19.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
25 currently pending
Career history
641
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
59.7%
+19.7% vs TC avg
§102
13.8%
-26.2% vs TC avg
§112
16.7%
-23.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 603 resolved cases

Office Action

§103 §DOUBLEPATENT
DETAILED ACTION Note: The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This Office action is in response to communications filed July 14, 2026. Election/Restrictions 1. Applicant’s election without traverse of Claims 21-46 in the reply filed on July 14, 2026 is acknowledged. Claims 47-48 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Claims 47-48 have been subsequently canceled. Status of Claims 2. Claims 21-46 are pending and currently under consideration for patentability. Claims 47-48 are canceled as of the July 14, 2026 election. Priority 3. Applicant’s claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, or 365(c) is acknowledged. Double Patenting 4. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. 5. Claims 21-46 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-66 of U.S. Patent No. 11,944,519 B2. Although the claims at issue are not identical, they are not patentably distinct from each other because patented claims 1-66 contain additional limitations requiring the final layered construction to have at least three adhesive layers, being viscoelastic along any axis, and wherein the thickness of at least a portion of the final layered construction includes at least the at least three adhesive layer, and is thus more specific, in effect making the invention of patented claims 1-66 a "species" of the "generic" invention of instant claims 21-46. It has been held that the generic invention is "anticipated" by the species. See In re Goodman, 29 USPQ2d 2010 (Fed. Cir. 1993). Additionally, the claimed method steps of the instant invention, namely selecting the dressing component, removing the removable liner, and placing the first surface onto the skin surrounding the wound, are all well-understood and obvious method steps of installing an adhesive drape of a wound dressing for use with a patient, particularly the adhesive drape claimed in patented claim 1 of US 11,944,519. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. 6. Claim(s) 21-22, 24-28, 30, 32-33, 36, 38-39 and 43 are rejected under 35 U.S.C. 103 as being unpatentable over Sheridan et al. (US PGPUB 2008/0280086 A1) in view of Estes et al. (US PGPUB 2009/0152137 A1). 7. With regard to claims 21 and 22, Sheridan discloses a method of constructing a dressing (multi-layer assembly, 10) over a wound penetrating a surface of a skin ([0161]; abstract; Fig. 1), comprising: selecting a wound dressing component (10) made by a manufacturing process (the steps involved in forming the tape are interpreted as being the process of manufacturing the tape; see method of making the assembly in para [0151]), suitable for covering the wound and suitable for adhering to the skin around the wound ([0161]; “surgical drape”, “wound care”), comprising an unbacked (backing is “optional” and not utilized in Fig.1 embodiment; [0126]), layered adhesive drape construction (10 including first layer, 12 and second layer, 14) (a) defining first and second surfaces (outer surfaces of 12 and 14), the second surface facing oppositely to the first surface (Fig. 1), (b) defining a perimeter having at least one outer edge (drapes are constructed with outer peripheral edges which define a perimeter as shown in Fig. 1), (c) being formed of at least a first adhesive (12) and a second adhesive (14), the second adhesive derived from a different adhesive formula than a first adhesive formula (the first layer 12 is a silicone based PSA and the second layer 14 is an elastomer based PSA), and (d) (ii) having at least two adhesive layers (first layer 12 of silicone based PSA and second layer 14 of elastomer based PSA form a layered construction as shown in figure 1), each adhesive layer being at least one of at least partially (1) dried as a solid coating or a pattern coating and/or (2) cured as a solid coating or a pattern coating (second layer 14 that includes an elastomer-based PSA; [0047]; can be continuous or discontinuous; [0155]), the at least two adhesive layers (12, 14) being assembled into a final layered construction (the assembly 10 includes a first and second layer 12,14 as shown in figure 1 – this is interpreted as being a “final layered construction” as it is capable of use in this form), wherein at least a portion of the final layered construction has a thickness that includes at least the at least two adhesive layers (the assembly 10 includes a first and second layer 12,14 as shown in figure 1 wherein each of the first and second PSA layers 12,14 is from 0.1-40mils thick – [0101;0124]; thus, the total thickness for the assembly is a combination of the thickness of these two layers), wherein the final layered construction is constructed without a backing (Fig. 1; [0126]) and is constructed as a solid coating or a pattern coating (adhesive can be continuous or discontinuous – [0155]) and wherein at least a portion of at least the first surface is at least one biocompatible adhesive (12) capable of adhering to the skin during functional use of the drape construction (10; the PSA article is disclosed as being suitable for use in medical applications such as in surgical drapes, bandages and wound care - [0161] thus, it is inherent that the PSA of layers 12 and/or 14b is biocompatible in order to render the device “suitable” for application to a user’s skin in medical applications where direct application to a user’s skin is required, such as in the case of bandages and wound care applications), the at least one biocompatible adhesive being at least the first adhesive (12; Fig. 1); and removing at least one removable liner (release liner 8 covers the upper surface of first layer 12 as shown in Fig. 1) from covering at least a portion of at least the first surface (12) of the drape construction (10; [0049-0052]; it is inherent that the liner 8 must be removed for application to the user’s skin and, furthermore, that the drape must first be adhered to the skin before it can thereafter be removed). Sheridan does not explicitly disclose that the adhesive layers are assembled into a final layered construction during the manufacturing process before packaging. However, Sheridan not only teaches assembly of the adhesive layers into a final layered product (the assembly 10 includes a first and second layer 12,14 as shown in Fig. 1 – this is interpreted as being a “final layered construction” as it is capable of use in this form) but, also, teaches packaging of the product ([0163]) Therefore, it would have been obvious to one having ordinary skill in the art prior to the effective filing date of the claimed invention to have modified the wound dressing component disclosed by Sheridan to be packaged as an already final layered product, in order to provide the dressing component in a ready-to-use form for user convenience, with a reasonable expectation of success. Additionally, while Sheridan discloses that the PSA article (10) is suitable for use in medical applications such as in surgical drapes, bandages and wound care ([0161] thus, it is inherent that the PSA of layers 12 and/or 14b is biocompatible in order to render the device “suitable” for application to a user’s skin in medical applications where direct application to a user’s skin is required, such as in the case of bandages and wound care applications), Sheridan fails to explicitly disclose the method steps of covering at least a portion of the wound with at least a portion of the drape construction; and placing at least a portion of the first surface of the drape construction onto the skin surrounding the wound to adhere the drape construction to the skin. Within the same field of medical adhesive drapes, Estes discloses a combined skin sealant and incise drape (abstract; Figs. 1, 2, 19), including the method steps of covering at least a portion of the wound (incision) with at least a portion of the drape construction (incise drape, 10; [0047]; [0053]); and placing at least a portion of the first surface (lower surface, 18) of the drape construction (10) onto the skin surrounding the wound (incision) to adhere the drape construction to the skin ([0056]; Figs. 1, 19). Therefore, it would have been obvious to one having ordinary skill in the art prior to the effective filing date of the claimed invention to have modified the method disclosed by Sheridan to include the steps of covering the wound and placement on the surrounding skin, similar to that disclosed by Estes, in order to utilize the dressing as a surgical drape, bandage or wound care component, as intended by Sheridan in paragraph [0161], and to provide an anchor to the wound site as well as to provide a complete, intact draped closure over the surgical site, as suggested by Estes in paragraph [0056]. 8. With regard to claim 24, Sheridan discloses that the drape construction (10) is planar and wherein the drape construction as a whole has an elastic recovery from 50 percent stretch of at least 75% in at least one direction in the plane ([0102]; elastomers are inherently viscoelastic; thus, the assembly 10 which is formed from elastomers is interpreted as being viscoelastic along at least one axis in the plane of the material; the at least one axis is interpreted as being a selected axis). 9. With regard to claim 25, the claim is obvious in view of Sheridan and Estes because with respect to the method steps claimed (i.e. stretching at a strain rate of 0.225/sec to 0.300/sec to provide (i) an effective uniaxial modulus of elasticity below 1.0MPa for the small strain range of 0 to 0.1, (ii) an effective uniaxial modulus of elasticity below 0.8MPa for the small strain range of 0 to 0.2, (iii) a knee of its stress versus strain curve below a stress of 0.20MPa and/or (iv) a stress below 0.15MPa at a strain of 0.2), to the extent that the prior art apparatus meets the structural limitations of the apparatus, as claimed, it will also perform the method steps as claimed. Furthermore, it has been held that where the claimed and prior art products are identical or substantially identical in structure or composition, or are produced by identical or substantially identical processes, a prima facie case of either anticipation or obviousness has been established. In re Best, 562 F.2d 1252, 1255, 195 USPQ 430, 433 (CCPA 1977); MPEP 2112.01(I). In the present case, the device recited in claim 21 is identical to the device recited in claim 25 which is obvious in view of Sheridan and Estes (see claim rejections above). Since the prior art device of Sheridan is the same as the device for carrying out the method steps recited in claim 25, it follows that the device will perform the claimed process and, therefore, the method claimed is considered to be obvious over the prior art device. 10. With regard to claim 26, Sheridan discloses that the drape construction (10) is substantially impervious to fluid transfer through the thickness of the drape construction (the adhesive article is configured to be used in sealing applications e.g., gaskets, for liquids, vapors (e.g., moisture), and dust ([0161]) which inherently indicates that the article is impervious to fluid transfer because the material must be impervious to fluid transfer in order to function as a liquid seal). 11. With regard to claims 27-28, Sheridan is silent in regard to selecting at least one applicator, wherein the at least one applicator includes at least one porous material; and wherein placing the drape construction onto the skin further includes pressing on at least a portion of the second surface of the drape construction with the at least one porous material, wherein during the pressing, the at least one applicator does not apply any separate liquid sealant derived from at least one type of polymer compound to the second surface of the drape construction; or wherein placing the drape construction onto the skin further includes pressing on the second surface of the drape construction in the vicinity of any wrinkles in the drape construction. However, Estes discloses selecting at least one applicator (separate porous film, 36), wherein the at least one applicator (36) includes at least one porous material ([0060]); and wherein placing the drape construction (10) onto the skin further includes pressing on at least a portion of the second surface of the drape construction (10) in the vicinity of any wrinkles in the drape construction with the at least one porous material ([0056]; [0060]; “its use or non-use may be decided at the time the package is opened and the combined drape 10 is utilized”), wherein during the pressing, the at least one applicator (36) does not apply any separate liquid sealant derived from at least one type of polymer compound to the second surface of the drape construction ([0065]). Therefore, it would have been obvious to one having ordinary skill in the art prior to the effective filing date of the claimed invention to have modified the method disclosed by Sheridan to include the step of pressing an applicator against the second surface of the drape, similar to that disclosed by Estes, in order to more evenly place the seal of the drape against the skin during use, as suggested by Estes in paragraph [0060]. 12. With regard to claim 30, while Sheridan and Estes fail to explicitly disclose selecting at least one wound packing material; and packing the wound with the at least one wound packing material, Sheridan specifically suggests the use of its disclosed tape (10) as a surgical drape, a bandage and in wound care. Accordingly, it would have been obvious to one having ordinary skill in the art prior to the effective filing date of the claimed invention to have modified the method disclosed by Sheridan in view of Estes to include the step of selecting a wound packing material and packing the wound, similar to how Sheridan utilizes the drape in wound care, since it is well-known and widely recognized in the field of wound dressings that wound packing material can greatly assist in the absorption of wound exudate, while also assisting in overall wound healing process, and packing the wound prior to application of the drape construction disclosed by Sheridan in view of Estes would lead to an overall positive in wound healing progress, as opposed to without a wound packing. 13. With regard to claims 32 and 33, while Sheridan is silent in regard to the method steps of claims 32 and 33, Estes discloses selecting at least one container (150) of at least one sealant component (12; the skin sealant is interpreted as being a “dressing to skin interface” because it is disposed on the incise drape and the combination skin sealant and incise drape is applied to a patient's skin such that the skin sealant is positioned adjacent the skin and the incise drape is positioned over the skin sealant and the skin – thus the adhesive is the interface between a user’s skin and the drape), that is capable of being delivered as a sealant in a liquid state at pre-selected ambient conditions (fully capable); during and/or after placing the drape construction (10) onto the skin, applying the sealant, that is in the liquid state as applied (the sealant forms a coherent film with strong adhesion to the skin – para [0005] and substantially fills contours of the incise drape such that any air pockets and wrinkles positioned between the incise drape and the skin sealant are sealed and isolated from the skin – para [0010]), on at least a portion of the at least one outer edge of the drape construction (10) and at least the skin adjacent to at least the portion of the at least one outer edge of the drape construction (10) in at least one sealant layer (the sealant 12 is applied to the edge because “when applied to the incision site, the skin sealant 12 extends at least to an outer edge of the defined reservoir 24, and desirably beyond – para [0059]; sealant is interpreted as being applied after the adhesive surface of the drape is applied to the skin in order for the sealant to thereby form an occlusive seal with the skin), the sealant being at least partially cross-linked after at least one of drying and/or curing ([0005-0006]); and at least one of drying and/or curing the sealant within thirty minutes after application of the sealant as the at least one sealant layer on at least the portion of the at least one outer edge of the drape construction (fully capable); wherein applying the sealant, that is in the liquid state as applied, includes applying the sealant over at least the portion of the at least one outer edge of the drape construction and on at least the second surface of the drape construction adjacent to at least the portion of the at least one outer edge of the drape construction and at least the skin adjacent to at least the portion of the at least one outer edge of the drape construction in at least one sealant layer (forms an occlusive or airtight bond because sealant 12 forms a coherent film with strong adhesion to the skin - para [0005] and substantially fills contours of the incise drape such that any air pockets and wrinkles positioned between the incise drape and the skin sealant are sealed and isolated from the skin – para [0010]). Therefore, it would have been obvious to one having ordinary skill in the art prior to the effective filing date of the claimed invention to have modified the method disclosed by Sheridan in view of Estes to include the step of selecting and applying sealant along the edges, similar to that disclosed by Estes, in order to form an occlusive/airtight bond between the skin and the edges of the drape, substantially filling any contours of the drape such that any air pockets and wrinkles are sealed and isolated from the skin, as suggested by Estes in paragraph [0010]. 14. With regard to claim 36, Sheridan and Estes fail to explicitly disclose that at least one adhesive of the drape construction and a majority of the sealant after the at least one of drying and/or curing are each derived from at least one type of rubber compound that is not silicone-based, but it would have been obvious to one having ordinary skill in the art, before the effective filing date of the invention, to have used such an adhesive and sealant since it is within the general skill of a worker in the art to select a known material on the basis of its suitability for the intended use as a matter of obvious design choice. 15. With regard to claims 38 and 39, Sheridan discloses that the wound dressing component (10) is suitable to remove from the skin without damaging the skin by stretching the component ([0150]); and further including removing the drape construction (10) from the skin by applying a force of removal by stretching the drape construction in a direction wherein the drape construction is lifted less than or equal to 45 degrees from the surface of the skin (Fig. 5B; [0150]). 16. With regard to claim 43, While Sheridan is silent in regard to the claimed limitations, Estes discloses that the drape construction (10) is assembled during the manufacturing process before packaging to at least one other fluid-pervious material (clear porous film, 36; Fig. 1) to form a border dressing (Figs. 11-13, 17; [0055]; [0060]). Therefore, it would have been obvious to one having ordinary skill in the art prior to the effective filing date of the claimed invention to have modified the drape construction disclosed by Sheridan in view of Estes to be preassembled with one other fluid-pervious material, similar to that disclosed by Estes, in order to provide a more evenly placed skin sealant, as suggested by Estes in paragraph [0060]. 17. Claim(s) 29 and 40-42 are rejected under 35 U.S.C. 103 as being unpatentable over Sheridan in view of Estes, as applied to claim 21 above, and further in view of Willms et al (US 6,309,745). 18. With regard to claims 29 and 40-42, Sheridan and Estes fail to disclose during and/or after placing the drape construction onto the skin, removing at least one removable liner from covering at least a portion of at least the second surface of the drape construction; selecting at least one separate cover material, wherein the at least one separate cover material is capable of preventing from sticking to other surfaces at least a portion of the second surface of the drape construction after placing at least the portion of the first surface onto the skin; and during and/or after placing at least the portion of the first surface onto the skin,covering at least a portion of the second surface of the drape construction with at least one separate cover material; wherein the at least one separate cover material is at least one powder and/or fine, solid particulate material or paint material. However, within the same field of adhesive drapes, Willms discloses an adhesive tape wherein the adhesive can comprise a print coverage thereon covering the layer in order to adjust a reduced adhesive retention force and thereby prevent sticking, wherein the coverage material can be a material like paint or powder (col 2 line 63 – col 3 line 1). Therefore, it would have been obvious to one having ordinary skill in the art prior to the effective filing date of the claimed invention to have modified the drape construction disclosed by Sheridan in view of Estes to include at least one powder/paint removable liner from covering at least a portion of the second surface of the drape, similar to that disclosed by Willms in order to adjust a reduced adhesive retention force, as suggested by Willms in col 2 line 63 – col 3 line 1. Sheridan in view of Estes and Willms does not, however, disclose that the separate cover material prevents sticking to other surfaces after a portion of the first surface is applied to the surface of the tissue. However, to the extent that the prior art apparatus meets the structural limitations of the claimed apparatus, it is obvious that during normal use of the prior art device that the prior art will also perform the method steps as claimed. Furthermore, it has been held that where the claimed and prior art products are identical or substantially identical in structure or composition, or are produced by identical or substantially identical processes, a prima facie case of either anticipation or obviousness has been established. In re Best, 562 F.2d 1252, 1255, 195 USPQ 430, 433 (CCPA 1977); MPEP 2112.01(I). In the present case, the device recited in the instant claims is substantially identical to the device recited in Sheridan in view of Willms. Since the prior art device is substantially the same as the device for carrying out the claimed method, it would have been obvious to one having ordinary skill in the art, prior to the effective filing date of the invention, that the device of Sheridan in view of Estes and Willms will perform the claimed process because the method as claimed is nothing more than the expected steps involved for normal and usual use of the device by an intended user. 19. Claim(s) 31, 37, 44 and 45 are rejected under 35 U.S.C. 103 as being unpatentable over Sheridan in view of Estes, as applied to claim 21 above, and further in view of Hu et al. (US PGPUB 2010/0137775 A1). 20. With regard to claims 31, 37, 44 and 45, Sheridan and Estes fail to disclose selecting an interface comprising at least one of (1) at least one flexible tube having a first end and a second end, (2) at least one flange having a central passage through which a first end of a tube is insertable, (3) at least one flange having a central passage capable of communicating with a connector that is capable of mating with a first end of a tube and/or (4) at least one flange having a central passage communicating with a connector that is capable of mating with a first end of a tube; selecting at least one source of negative pressure; during and/or after placing the drape construction onto the skin, forming at least one sealed volume under the drape construction; connecting the at least one source of negative pressure to the drape construction, wherein the at least one source of negative pressure is configured to apply negative pressure to at least a portion of the at least one sealed volume; and applying negative pressure to at least the portion of the at least one sealed volume with the at least one source of negative pressure; and selecting at least one valve, wherein the at least one valve is capable of causing a controlled air leak; and positioning the at least one valve over the at least one sealed volume, wherein the at least one valve is capable of causing the controlled air leak to flow under the drape construction from outside of any sealed volume under the drape construction, wherein the controlled air leak is capable of causing liquid between the drape construction and the wound to flow towards the at least one source of negative pressure; wherein at least one of the at least one valve is at least one purge valve, the at least one purge valve being capable of causing the controlled air leak, wherein the controlled air leak is temporary. However, within the same field of wound draping, Hu discloses a device for delivery of reduced pressure to body surfaces (abstract; Fig. 1) including the steps of selecting an interface (port, 102) comprising at least one of (1) at least one flexible tube (tubing, 103) having a first end and a second end (Fig. 1; [0077]), (2) at least one flange (flange, 323; Fig. 3A) having a central passage (opening, 308) through which a first end of a tube (103) is insertable (Fig. 3A; [0081]); selecting at least one source of negative pressure (reduced pressure source; [0038]); during and/or after placing the drape construction (304) onto the skin, forming at least one sealed volume under the drape construction ([0052]; [0054]); connecting the at least one source of negative pressure to the drape construction ([0057-0059]), wherein the at least one source of negative pressure is configured to apply negative pressure to at least a portion of the at least one sealed volume ([0057-0059]); and applying negative pressure to at least the portion of the at least one sealed volume with the at least one source of negative pressure ([0057-0059]); and selecting at least one valve (203; [0004]; [0059]), wherein the at least one valve is capable of causing a controlled air leak ([0040]; [0042-0043]); and positioning the at least one valve (203) over the at least one sealed volume, wherein the at least one valve is capable of causing the controlled air leak to flow under the drape construction (304) from outside of any sealed volume under the drape construction ([0112]), wherein the controlled air leak is capable of causing liquid between the drape construction and the wound to flow towards the at least one source of negative pressure ([0038]; [0042]); wherein at least one of the at least one valve is at least one purge valve, the at least one purge valve being capable of causing the controlled air leak, wherein the controlled air leak is temporary ([0040]; [0042-0043]; [0112]). Therefore, it would have been obvious to one having ordinary skill in the art prior to the effective filing date of the claimed invention to have modified the method disclosed by Sheridan in view of Estes to include a selection of an interface, a source of negative pressure and a valve, similar to that disclosed by Hu, in order to utilize the adhesive drape as a surgical drape or wound care component for negative pressure wound dressing therapy, as suggested by Sheridan in paragraph [0161], and to provide fluid communication between a negative pressure source and the wound via a port, tubing and interposed valve, for inducing wound healing through sustained negative pressure at the wound bed, as suggested by Hu in paragraphs [0077-0080]. 21. Claim(s) 34 and 35 are rejected under 35 U.S.C. 103 as being unpatentable over Sheridan in view of Estes, as applied to claim 21 above, and further in view of Carte et al (US 5,947,917). 22. With regard to claims 34 and 35, while Estes discloses selecting at least one container (150) of at least one sealant component (12; the skin sealant is interpreted as being a “dressing to skin interface” because it is disposed on the incise drape and the combination skin sealant and incise drape is applied to a patient's skin such that the skin sealant is positioned adjacent the skin and the incise drape is positioned over the skin sealant and the skin – thus the adhesive is the interface between a user’s skin and the drape), that is capable of being delivered as a sealant in a liquid state at pre-selected ambient conditions (fully capable); during and/or after placing the drape construction (10) onto the skin, applying the sealant, that is in the liquid state as applied (the sealant forms a coherent film with strong adhesion to the skin – para [0005] and substantially fills contours of the incise drape such that any air pockets and wrinkles positioned between the incise drape and the skin sealant are sealed and isolated from the skin – para [0010]), on at least a portion of the at least one outer edge of the drape construction (10) and at least the skin adjacent to at least the portion of the at least one outer edge of the drape construction (10) in at least one sealant layer (the sealant 12 is applied to the edge because “when applied to the incision site, the skin sealant 12 extends at least to an outer edge of the defined reservoir 24, and desirably beyond – para [0059]; sealant is interpreted as being applied after the adhesive surface of the drape is applied to the skin in order for the sealant to thereby form an occlusive seal with the skin), Sheridan and Estes fail to disclose making at least one fold in the drape construction when placing at least the portion of the first surface of the drape construction onto the skin surrounding the wound; and pressing on the at least one fold in the drape construction to adhere the at least one fold to at least the second surface of the drape construction to lie flat on at least the second surface of the drape construction, the at least one fold having at least one edge after pressing; and during and/or after pressing on the at least one fold, applying the sealant, that is in the liquid state as applied, over the at least one edge of the at least one fold and at least one of (1) on at least the second surface of the drape construction in at least one sealant layer and/or (2) on at least the second surface of the drape construction and at least the skin adjacent to the drape construction in at least one sealant layer. However, within the same field of adhesive bandages, Carte discloses an adhesive bandage or tape (abstract; Fig. 1; col 3 lines 4-11) having a liner comprising two overlapping pieces that form a pull tab (col 6 lines 13-20; liners 16 and 18 covering adhesive 14 as shown in figure 1). Accordingly, it would have been obvious to one having ordinary skill in the art, before the effective filing date of the invention, to have modified the liner in Sheridan to have an overlapping adjacent liner covering the same surface of the tape as in Carte in order to provide a pull tab for grasping by a user to more easily facilitate application, as suggested by Carte in col 6 lines 13-20. Allowable Subject Matter 23. Claims 23 and 46 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Additionally, a non-statutory double patenting rejection has been applied against the instant claims and would necessitate a properly filed Terminal Disclaimer prior to placing the claims into condition for allowance. 24. Regarding claim 23, closest prior art of record fails to reasonably disclose or suggest, alone or in combination, the unique combination of claimed structure in claim 22, further requiring wherein the final layered construction has at least three adhesive layers and wherein the thickness of at least a portion of the final layered construction includes at least the at least three adhesive layers. 25. Regarding claim 46, closest prior art of record fails to reasonably disclose or suggest, alone or in combination, the unique combination of claimed structure in claim 32, further requiring the step of selecting at least one applicator, wherein the at least one applicator includes at least one porous material, wherein at least one saturation liquid saturates at least a portion of the at least one porous material, wherein the at least one saturation liquid is not the sealant and/or any sealant component; and wherein applying the sealant, that is in the liquid state as applied, includes pressing on at least a portion of the at least one outer edge of the drape construction with at least a portion of the at least one porous material, wherein at least a portion of the at least one porous material is at least damp with the at least one saturation liquid and contacts the sealant in the liquid state.. Conclusion 26. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Wiedner et al. (US 5,860,420) discloses a surgical draping system having a reusable and disposable component. 27. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ANDREW J MENSH whose telephone number is (571)270-1594. The examiner can normally be reached M-F 9 a.m. - 6 p.m.. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sarah Al-Hashimi can be reached at (571)272-7159. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ANDREW J MENSH/ Primary Examiner, Art Unit 3781
Read full office action

Prosecution Timeline

Feb 29, 2024
Application Filed
Sep 23, 2026
Non-Final Rejection mailed — §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12773339
CONTAINER FOR COLLECTING LIQUID FOR TRANSPORT
5y 3m to grant Granted Oct 27, 2026
Patent 12758356
APPLICATION AID FOR THE TREATMENT OF WOUNDS
5y 8m to grant Granted Oct 13, 2026
Patent 12752057
SYRINGE ASSEMBLY INCLUDING PRESSURIZED STERILE AIR
1y 6m to grant Granted Oct 06, 2026
Patent 12745935
SURGICAL SUCTION DEVICE THAT USES POSITIVE PRESSURE GAS
5y 8m to grant Granted Sep 29, 2026
Patent 12746145
HUMAN INTERFACE DEVICE FOR URINARY RELIEF SYSTEM
3y 6m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
64%
Grant Probability
84%
With Interview (+19.4%)
3y 6m (~10m remaining)
Median Time to Grant
Low
PTA Risk
Based on 603 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month